Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

297 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Hanauer SB, et al. Among authors: panaccione r. Gastroenterology. 2006 Feb;130(2):323-33; quiz 591. doi: 10.1053/j.gastro.2005.11.030. Gastroenterology. 2006. PMID: 16472588 Clinical Trial.
Successful management of Crohn's disease of the ileoanal pouch with infliximab.
Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Ricart E, et al. Among authors: panaccione r. Gastroenterology. 1999 Aug;117(2):429-32. doi: 10.1053/gast.1999.0029900429. Gastroenterology. 1999. PMID: 10419926
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Ricart E, et al. Among authors: panaccione r. Am J Gastroenterol. 2001 Mar;96(3):722-9. doi: 10.1111/j.1572-0241.2001.03612.x. Am J Gastroenterol. 2001. PMID: 11280541
Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.
Panaccione R; Canadian Consensus Group on the use of infliximab in Crohn's disease. Panaccione R, et al. Can J Gastroenterol. 2001 Jun;15(6):371-5. doi: 10.1155/2001/490921. Can J Gastroenterol. 2001. PMID: 11429666 Review.
Giant cell myocarditis, in a patient with Crohn's disease, treated with etanercept--a tumour necrosis factor-alpha antagonist.
Nash CL, Panaccione R, Sutherland LR, Meddings JB. Nash CL, et al. Among authors: panaccione r. Can J Gastroenterol. 2001 Sep;15(9):607-11. doi: 10.1155/2001/954340. Can J Gastroenterol. 2001. PMID: 11573104
Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG, Enns R, Fedorak RN, Panaccione R, Paré P, Steinhart AH, Wild G. Feagan BG, et al. Among authors: panaccione r. Can J Clin Pharmacol. 2001 Winter;8(4):188-98. Can J Clin Pharmacol. 2001. PMID: 11743591 Review.
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.
Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. Schwartz DA, et al. Among authors: panaccione r. Gastroenterology. 2002 Apr;122(4):875-80. doi: 10.1053/gast.2002.32362. Gastroenterology. 2002. PMID: 11910338
Medical therapy of Crohn disease.
Panaccione R, Sandborn WJ. Panaccione R, et al. Curr Opin Gastroenterol. 2004 Jul;20(4):351-9. doi: 10.1097/00001574-200407000-00009. Curr Opin Gastroenterol. 2004. PMID: 15703664
Advances in medical therapy of inflammatory bowel disease.
Panaccione R, Ferraz JG, Beck P. Panaccione R, et al. Curr Opin Pharmacol. 2005 Dec;5(6):566-72. doi: 10.1016/j.coph.2005.08.003. Epub 2005 Oct 6. Curr Opin Pharmacol. 2005. PMID: 16213789 Review.
Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Sandborn WJ, et al. Among authors: panaccione r. N Engl J Med. 2005 Nov 3;353(18):1912-25. doi: 10.1056/NEJMoa043335. N Engl J Med. 2005. PMID: 16267322 Clinical Trial.
297 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback